Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Investor Presentation (June 2024)
10 slides from Optomed Oyj Class A's investor presentation, June 2024
Slide 1: Optomed in Brief
Investor Presentation, June 2024 Optomed in Brief
Slide 2: The prevalence of eye diseases is expected to rapidly increase, which increases the need for screening
The prevalence of eye diseases is expected to rapidly increase, which again increases the need for screening Aging population Diabetes growing AI Prevalence of serious eye Diabetic Retinopathy (causing Technological advances in artificial diseases (causing vision loss) vision loss) affects ~35% of a
Slide 3: Transition from traditional desktop cameras to AI integrated handheld cameras has started
Transition from traditional desktop cameras to AI integrated handheld cameras has started Optomed’s handheld Traditional equipment …together with AI camera… • Large initial investments • Cost efficient • Saves eye doctor resources • Not usable in primary care • Possibility to increase and lowers cos
Slide 4: Optomed is the leading handheld camera + AI company
Optomed is the leading handheld camera + AI company HQ and product development in Finland Revenue 15 MEUR (2023) Over 60 distributors in 50 countries; several OEM partners Own sales organisation and client base Office Outsourced Several AI partnerships e.g. manufacturing AEYE Health Ltd, Eyenuk Inc.
Slide 5: FDA Clearance in Q2/2024
FDA Clearance in Q2/2024 • Optomed Aurora IQ is the first handheld device + a fully autonomous AI to receive FDA clearance for diagnosis of referable diabetic retinopathy • Two large-scale prospective phase-III studies, in which the solution demonstrated best-in- class efficacy and imageability • 92
Slide 6: Transition to recurring revenue model in the US
Transition to recurring revenue model in the US Previously, Optomed has sold its devices in capex model. The AI readiness enables service-based model Market Complete Solution Recurring Revenue Model From product sales to complete screening Already stablished reimbursement solutions with diagnosis So
Slide 7: Benefits for customers and clinics in the US
Benefits for customers and clinics in the US Target customers are healthcare professionals from primary care to hospitals, eye clinics and optics stores + No initial investments, only monthly rental fee + High reimbursement, >USD 41, per diabetic (2024 national average) which is higher than the reim
Slide 8: Expansion to other disease screenings with AI
Expansion to other disease screenings with AI The markets for other diseases and preventive health-checks in primary care are significantly larger than the current ophthalmology market FUTURE: Preventive health-check in primary care Eye disease, neurological disorders, Alzheimer’s disease, cardiovas
Slide 9: Co-operation with Toku Q2/2024
Co-operation with Toku Q2/2024 • Optomed and Toku Inc. entered a partnership to commercialize AI CLAiR and BioAge • CLAiR is cardiovascular risk detection algorithm that has recently been granted the FDA’s Breakthrough Device designation • BioAge is an algorithm for assessing a person’s biological a
Slide 10: investors@optomed.com www.optomed.com
investors@optomed.com www.optomed.com